The drug, ACI193, was well tolerated in the first trial testing it in people, the company said. Results of the randomised, placebo-controlled study of 62 patients with early Alzheimer's disease were presented at the Alzheimer's Association's International Conference in Amsterdam.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/AZ6k4PS
Home »
Information and Updates: ET HealthWorld : ETHealthworld.com
,
Top Health News | Latest Healthcare Sector & Healthcare Industry news
» Acumen's Alzheimer's drug passes initial safety test
https://ift.tt/pveVYk6
No comments:
Post a Comment